Use of cell-penetrating-peptides in Oligonucleotide splice switching therapy

Current Gene Therapy

Volumn 12, Issue 3, 2012, Pages 161-178

  El Andaloussi, Samir A ^a   Hammond, Suzan M ^a   Mäger, Imre ^a   Wood, Matthew J A ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Cell penetrating peptides; Covalent conjugates; Duchenne muscular dystrophy; Nanoparticles; Oligonucleotides; Spinal muscular atrophy; Splice switching

Indexed keywords

ARGININE; CELL PENETRATING PEPTIDE; LIPOPLEX; NUCLEIC ACID; OLIGONUCLEOTIDE; PENETRATIN; SPLICE SWITCHING OLIGONUCLEOTIDE; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; CARDIOMYOPATHY; DUCHENNE MUSCULAR DYSTROPHY; GENE CONTROL; GENE DELIVERY SYSTEM; GENE MUTATION; GENE TARGETING; HUMAN; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; REVIEW; RNA SPLICING; SPINAL MUSCULAR ATROPHY;

ALTERNATIVE SPLICING; CELL MEMBRANE; CELL-PENETRATING PEPTIDES; GENE EXPRESSION REGULATION; HUMANS; MICRORNAS; MOLECULAR TARGETED THERAPY; MUSCULAR ATROPHY, SPINAL; MUSCULAR DYSTROPHY, DUCHENNE; NANOPARTICLES; OLIGONUCLEOTIDES; RNA PRECURSORS; RNA, DOUBLE-STRANDED;

EID: 84862629948     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/156652312800840612     Document Type: Review

References (199)

1. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature 2001; 409: 860-921.
2. Ahi YS, Bangari DS, Mittal SK. Adenoviral vector immunity: its implications and circumvention strategies. Curr Gene Ther 2011; 11: 307-20.
3. Mingozzi F, High KA. Immune responses to AAV in clinical trials.Curr Gene Ther 2011; 11: 321-30.
4. Paterson BM, Roberts BE, Kuff EL. Structural gene identificationand mapping by DNA-mRNA hybrid-arrested cell-free translation. Proc Natl Acad Sci USA 1977; 74: 4370-4.
5. Stephenson ML, Zamecnik PC. Inhibition of Rous sarcoma viralRNA translation by a specific oligodeoxyribonucleotide. Proc Natl Acad Sci USA 1978; 75: 285-8.
6. Crooke ST. Progress in antisense technology. Annu Rev Med 2004;55: 61-95.
7. Kang SH, Cho MJ, Kole R. Up-regulation of luciferase geneexpression with antisense oligonucleotides: implications and applications in functional assay development. Biochemistry 1998; 37: 6235-9.
8. Hoke GD, Draper K, Freier SM, et al. Effects of phosphorothioatecapping on antisense oligonucleotide stability, hybridization and antiviral efficacy versus herpes simplex virus infection. Nucleic Acids Res 1991; 19: 5743-8.
9. Campbell JM, Bacon TA, Wickstrom E. Oligodeoxynucleosidephosphorothioate stability in subcellular extracts, culture media, sera and cerebrospinal fluid. J Biochem Biophys Methods 1990; 20: 259-67.
10. Levin AA. A review of the issues in the pharmacokinetics andtoxicology of phosphorothioate antisense oligonucleotides. Biochim Biophys Acta 1999; 1489: 69-84.
11. Brown DA, Kang SH, Gryaznov SM, et al. Effect ofphosphorothioate modification of oligodeoxynucleotides on specific protein binding. J Biol Chem 1994; 269: 26801-5.
12. LaPlanche LA, James TL, Powell C, et al. Phosphorothioate-modified oligodeoxyribonucleotides. III. NMR and UV spectroscopic studies of the Rp-Rp, Sp-Sp, and Rp-Sp duplexes, [d(GGSAATTCC)]2, derived from diastereomeric O-ethyl phosphorothioates. Nucleic Acids Res 1986; 14: 9081-93.
13. Jabs DA, Griffiths PD. Fomivirsen for the treatment ofcytomegalovirus retinitis. Am J Ophthalmol 2002; 133: 552-6.
14. Kurreck J, Wyszko E, Gillen C, Erdmann VA. Design of antisenseoligonucleotides stabilized by locked nucleic acids. Nucleic Acids Res 2002; 30: 1911-8.
15. Burnett JR. Drug evaluation: ISIS-301012, an antisenseoligonucleotide for the treatment of hypercholesterolemia. Curr Opin Mol Ther 2006; 8: 461-7.
16. Myers KJ, Witchell DR, Graham MJ, Koo S, Butler M, CondonTP. Antisense oligonucleotide blockade of alpha 4 integrin prevents and reverses clinical symptoms in murine experimental autoimmune encephalomyelitis. J Neuroimmunol 2005; 160: 12-24.
17. Lennox KA, Behlke MA. A direct comparison of anti-microRNAoligonucleotide potency. Pharm Res 2010; 27: 1788-99.
18. Eder PS, DeVine RJ, Dagle JM, Walder JA. Substrate specificityand kinetics of degradation of antisense oligonucleotides by a 3' exonuclease in plasma. Antisense Res Dev 1991; 1: 141-51.
19. Zamaratski E, Pradeepkumar PI, Chattopadhyaya J. A criticalsurvey of the structure-function of the antisense oligo/RNA heteroduplex as substrate for RNase H. J Biochem Biophys Methods 2001; 48: 189-208.
20. Wu H, Lima WF, Zhang H, Fan A, Sun H, Crooke ST.Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs. J Biol Chem 2004; 279: 17181-9.
21. Monia BP, Lesnik EA, Gonzalez C, et al. Evaluation of 2'-modifiedoligonucleotides containing 2'-deoxy gaps as antisense inhibitors of gene expression. J Biol Chem 1993; 268: 14514-22.
22. Stein CA, Hansen JB, Lai J, et al. Efficient gene silencing by deliveryof locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucleic Acids Res 2010; 38: e3.
23. Koshkin AA, Wengel J. Synthesis of Novel 2',3'-Linked BicyclicThymine Ribonucleosides. J Org Chem 1998; 63: 2778-81.
24. Bondensgaard K, Petersen M, Singh SK, et al. Structural studies ofLNA:RNA duplexes by NMR: conformations and implications for RNase H activity. Chemistry 2000; 6: 2687-95.
25. Roberts J, Palma E, Sazani P, Orum H, Cho M, Kole R. Efficientand persistent splice switching by systemically delivered LNA oligonucleotides in mice. Mol Ther 2006; 14: 471-5.
26. Wahlestedt C, Salmi P, Good L, et al. Potent and nontoxicantisense oligonucleotides containing locked nucleic acids. Proc Natl Acad Sci USA 2000; 97: 5633-8.
27. Guterstam P, Lindgren M, Johansson H, et al. Splice-switchingefficiency and specificity for oligonucleotides with locked nucleic acid monomers. Biochem J 2008; 412: 307-13.
28. Lindholm MW, Elmen J, Fisker N, et al. PCSK9 LNA AntisenseOligonucleotides Induce Sustained Reduction of LDL Cholesterol in Nonhuman Primates. Mol Ther 2011; In press.
29. Lanford RE, Hildebrandt-Eriksen ES, Petri A, et al. Therapeuticsilencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010; 327: 198-201.
30. Elmen J, Lindow M, Schutz S, et al. LNA-mediated microRNAsilencing in non-human primates. Nature 2008; 452: 896-9.
31. Stirchak EP, Summerton JE, Weller DD. Uncharged stereoregularnucleic acid analogs: 2. Morpholino nucleoside oligomers with carbamate internucleoside linkages. Nucleic Acids Res 1989; 17: 6129-41.
32. Summerton J. Morpholino antisense oligomers: the case for anRNase H-independent structural type. Biochim Biophys Acta 1999; 1489: 141-58.
33. Wood MJ. Toward an oligonucleotide therapy for Duchennemuscular dystrophy: a complex development challenge. Sci Transl Med 2010; 2: 25ps15.
34. Nielsen PE, Egholm M, Berg RH, Buchardt O. Sequence-selectiverecognition of DNA by strand displacement with a thymine-substituted polyamide. Science 1991; 254: 1497-500.
35. Egholm M, Buchardt O, Christensen L, et al. PNA hybridizes tocomplementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules. Nature 1993; 365: 566-8.
36. Pooga M, Soomets U, Hallbrink M, et al. Cell penetrating PNAconstructs regulate galanin receptor levels and modify pain transmission in vivo. Nat Biotechnol 1998; 16: 857-61.
37. Sazani P, Gemignani F, Kang SH, et al. Systemically deliveredantisense oligomers upregulate gene expression in mouse tissues. Nat Biotechnol 2002; 20: 1228-33.
38. Wahl MC, Will CL, Luhrmann R. The spliceosome: designprinciples of a dynamic RNP machine. Cell 2009; 136: 701-18.
39. Kramer A. The structure and function of proteins involved inmammalian pre-mRNA splicing. Annu Rev Biochem 1996; 65: 367-409.
40. Breathnach R, Benoist C, O'Hare K, Gannon F, Chambon P.Ovalbumin gene: evidence for a leader sequence in mRNA and DNA sequences at the exon-intron boundaries. Proc Natl Acad Sci USA 1978; 75: 4853-7.
41. Gao K, Masuda A, Matsuura T, Ohno K. Human branch pointconsensus sequence is yUnAy. Nucleic Acids Res 2008; 36: 2257-67.
42. Cooper TA, Wan L, Dreyfuss G. RNA and disease. Cell 2009; 136:777-93.
43. Dobkin C, Pergolizzi RG, Bahre P, Bank A. Abnormal splice in amutant human beta-globin gene not at the site of a mutation. Proc Natl Acad Sci U S A 1983; 80: 1184-8.
44. Cheng TC, Orkin SH, Antonarakis SE, et al. beta-Thalassemia inChinese: use of in vivo RNA analysis and oligonucleotide hybridization in systematic characterization of molecular defects. Proc Natl Acad Sci U S A 1984; 81: 2821-5.
45. Treisman R, Orkin SH, Maniatis T. Specific transcription and RNAsplicing defects in five cloned beta-thalassaemia genes. Nature 1983; 302: 591-6.
46. Jones CT, McIntosh I, Keston M, Ferguson A, Brock DJ. Threenovel mutations in the cystic fibrosis gene detected by chemicalcleavage: analysis of variant splicing and a nonsense mutation. Hum Mol Genet 1992; 1: 11-7.
47. Dominski Z, Kole R. Restoration of correct splicing in thalassemicpre-mRNA by antisense oligonucleotides. Proc Natl Acad Sci USA 1993; 90: 8673-7.
48. Wein N, Avril A, Bartoli M, et al. Efficient bypass of mutations indysferlin deficient patient cells by antisense-induced exon skipping. Hum Mutat 2010; 31: 136-42.
49. Singh NK, Singh NN, Androphy EJ, Singh RN. Splicing of acritical exon of human Survival Motor Neuron is regulated by a unique silencer element located in the last intron. Mol Cell Biol 2006; 26: 1333-46.
50. Burglen L, Spiegel R, Ignatius J, et al. SMN gene deletion in variantof infantile spinal muscular atrophy. Lancet 1995; 346: 316-7.
51. Lorson CL, Hahnen E, Androphy EJ, Wirth B. A single nucleotidein the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci USA 1999; 96: 6307-11.
52. Monani UR, Lorson CL, Parsons DW, et al. A single nucleotidedifference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum Mol Genet 1999; 8: 1177-83.
53. Kashima T, Manley JL. A negative element in SMN2 exon 7inhibits splicing in spinal muscular atrophy. Nat Genet 2003; 34: 460-3.
54. Cartegni L, Krainer AR. Disruption of an SF2/ASF-dependentexonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1. Nat Genet 2002; 30: 377-84.
55. Passini MA, Bu J, Richards AM, et al. Antisense oligonucleotidesdelivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci Transl Med 2011; 3: 72ra18.
56. Porensky PN, Mitrpant C, McGovern VL, et al. A singleadministration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse. Hum Mol Genet 2012; 21: 1625-38.
57. Hua Y, Sahashi K, Rigo F, et al. Peripheral SMN restoration isessential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature 2011; 478: 123-6.
58. Davies KE, Nowak KJ. Molecular mechanisms of musculardystrophies: old and new players. Nat Rev Mol Cell Biol 2006; 7: 762-73.
59. England SB, Nicholson LV, Johnson MA, et al. Very mildmuscular dystrophy associated with the deletion of 46% of dystrophin. Nature 1990; 343: 180-2.
60. Monaco AP, Bertelson CJ, Liechti-Gallati S, Moser H, Kunkel LM. Anexplanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 1988; 2: 90-5.
61. Aartsma-Rus A, Janson AA, Kaman WE, et al. Therapeuticantisense-induced exon skipping in cultured muscle cells from six different DMD patients. Hum Mol Genet 2003; 12: 907-14.
62. Aartsma-Rus A, Bremmer-Bout M, Janson AA, den Dunnen, JT, van Ommen GJ, van Deutekom JC. Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy. Neuromuscul Disord 2002; 12 (Suppl 1): S71-7.
63. Aartsma-Rus A, De Winter CL, Janson AA, et al. Functionalanalysis of 114 exon-internal AONs for targeted DMD exon skipping: indication for steric hindrance of SR protein binding sites. Oligonucleotides 2005; 15: 284-97.
64. van Deutekom JC, Bremmer-Bout M, Janson AA, et al. Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. Hum Mol Genet 2001; 10: 1547-54.
65. Sicinski P, Geng Y, Ryder-Cook AS, Barnard EA, Darlison MG. The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science 1989; 244: 1578-80.
66. Gebski BL, Mann CJ, Fletcher S, Wilton SD. Morpholino antisenseoligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle. Hum Mol Genet 2003; 12: 1801-11.
67. Heemskerk H, de Winter C, van Kuik P, et al. Preclinical PK andPD studies on 2'-O-methyl-phosphorothioate RNA antisense oligonucleotides in the mdx mouse model. Mol Ther 2010; 18: 1210-7.
68. Heemskerk HA, de Winter CL, de Kimpe SJ, et al. In vivocomparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping. J Gene Med 2009; 11: 257-66.
69. Alter J, Lou F, Rabinowitz A, et al. Systemic delivery ofmorpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med 2006; 12: 175-7.
70. Aartsma-Rus A, Fokkema I, Verschuuren J, et al. Theoreticapplicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat 2009; 30: 293-9.
71. van Deutekom JC, Janson AA, Ginjaar IB, et al. Local dystrophinrestoration with antisense oligonucleotide PRO051. N Engl J Med 2007; 357: 2677-86.
72. Kinali M, Arechavala-Gomeza V, Feng L, et al. Local restorationof dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol 2009; 8: 918-28.
73. Goemans NM, Tulinius M, van den Akker JT, et al. Systemicadministration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med 2011; 364: 1513-22.
74. Cirak S, Arechavala-Gomeza V, Guglieri M, et al. Exon skippingand dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 2011; 378: 595-605.
75. Lu QL, Rabinowitz A, Chen YC, et al. Systemic delivery ofantisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci USA 2005; 102: 198-203.
76. Malerba A, Thorogood FC, Dickson G, Graham IR. Dosingregimen has a significant impact on the efficiency of morpholino oligomer-induced exon skipping in mdx mice. Hum Gene Ther 2009; 20: 955-65.
77. Miller AD. Retrovirus packaging cells. Hum Gene Ther 1990; 1: 5-14.
78. Goyenvalle A, Babbs A, van Ommen GJ, Garcia L, Davies KE. Enhanced exon-skipping induced by U7 snRNA carrying a splicing silencer sequence: Promising tool for DMD therapy. Mol Ther 2009; 17: 1234-40.
79. Incitti T, De Angelis FG, Cazzella V, et al. Exon skipping andduchenne muscular dystrophy therapy: selection of the most active U1 snRNA antisense able to induce dystrophin exon 51 skipping. Mol Ther 2010; 18: 1675-82.
80. Meyer K, Marquis J, Trub J, et al. Rescue of a severe mouse modelfor spinal muscular atrophy by U7 snRNA-mediated splicing modulation. Hum Mol Genet 2009; 18: 546-55.
81. Gao X, Kim KS, Liu D. Nonviral gene delivery: what we know andwhat is next. AAPS J 2007; 9: E92-104.
82. Tiera MJ, Shi Q, Winnik FM, Fernandes JC. Polycation-based genetherapy: current knowledge and new perspectives. Curr Gene Ther 2011; 11: 288-306.
83. Zhang G, Budker V, Wolff JA. High levels of foreign geneexpression in hepatocytes after tail vein injections of naked plasmid DNA. Hum Gene Ther 1999; 10: 1735-7.
84. McCaffrey AP, Meuse L, Pham TT, et al. RNA interference inadult mice. Nature 2002; 418: 38-9.
85. Maruyama H, Higuchi N, Kameda S, et al. Rat kidney-targetednaked plasmid DNA transfer by retrograde injection into the renal vein. Mol Biotechnol 2004; 27: 23-31.
86. Hagstrom JE, Hegge J, Zhang G, et al. A facile nonviral method fordelivering genes and siRNAs to skeletal muscle of mammalian limbs. Mol Ther 2004; 10: 386-98.
87. Koller E, Vincent TM, Chappell A, De S, Manoharan M, BennettCF. Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes. Nucleic Acids Res 2011; 39: 4795-807.
88. Felgner PL, Gadek TR, Holm M, et al. Lipofection: a highlyefficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA 1987; 84: 7413-7.
89. Xu Y, Szoka FC, Jr. Mechanism of DNA release from cationicliposome/DNA Complexes used in cell transfection. Biochemistry 1996; 35: 5616-23.
90. Liu D, Ren T, Gao X. Cationic transfection lipids. Curr Med Chem2003; 10: 1307-15.
91. Scheule RK, St George JA, Bagley RG, et al. Basis of pulmonarytoxicity associated with cationic lipid-mediated gene transfer to the mammalian lung. Hum Gene Ther 1997; 8: 689-707.
92. Zimmermann TS, Lee AC, Akinc A, et al. RNAi-mediated genesilencing in non-human primates. Nature 2006; 441: 111-4.
93. Akinc A, Zumbuehl A, Goldberg M, et al. A combinatorial libraryof lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol 2008; 26: 561-9.
94. Khurana B, Goyal AK, Budhiraja A, Arora D, Vyas SP. siRNAdelivery using nanocarriers-an efficient tool for gene silencing. Current gene therapy 2010; 10: 139-55.
95. Semple SC, Akinc A, Chen J, et al. Rational design of cationiclipids for siRNA delivery. Nat Biotechnol 2010; 28: 172-6.
96. Zhang S, Zhao Y, Zhi D. Non-viral vectors for the mediation ofRNAi. Bioorg Chem 2011; In press.
97. Ferlini A, Sabatelli P, Fabris M, et al. Dystrophin restoration inskeletal, heart and skin arrector pili smooth muscle of mdx mice by ZM2 NP-AON complexes. Gene Ther 2010; 17: 432-8.
98. Wu B, Li Y, Morcos PA, Doran TJ, Lu P, Lu QL. Octa-guanidinemorpholino restores dystrophin expression in cardiac and skeletal muscles and ameliorates pathology in dystrophic mdx mice. Mol Ther 2009; 17: 864-71.
99. Popplewell LJ, Abu-Dayya A, Khana T, et al. Novel cationiccarotenoid lipids as delivery vectors of antisense oligonucleotides for exon skipping in Duchenne muscular dystrophy. Molecules 2012; 17: 1138-48.
100. Inaki Y, Ishikawa T, Takemoto K. Synthesis and interactions ofpoly-L-lysines containing nucleic acid bases. Nucleic Acids Symp Ser 1980: s137-40.
101. Boussif O, Lezoualc'h F, Zanta MA, et al. A versatile vector forgene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci USA 1995; 92: 7297-301.
102. Wightman L, Kircheis R, Rossler V, et al. Different behavior ofbranched and linear polyethylenimine for gene delivery in vitro and in vivo. J Gene Med 2001; 3: 362-72.
103. Derossi D, Joliot AH, Chassaing G, Prochiantz A. The third helixof the Antennapedia homeodomain translocates through biological membranes. J Biol Chem 1994; 269: 10444-50.
104. Lindgren M, Langel U. Classes and prediction of cell-penetratingpeptides. Methods Mol Biol 2011; 683: 3-19.
105. Vives E, Brodin P, Lebleu B. A truncated HIV-1 Tat protein basicdomain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 1997; 272: 16010-7.
106. Pooga M, Hallbrink M, Zorko M, Langel U. Cell penetration bytransportan. FASEB J 1998; 12: 67-77.
107. Wender PA, Mitchell DJ, Pattabiraman K, Pelkey ET, Steinman L, Rothbard JB. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc Natl Acad Sci U S A 2000; 97: 13003-8.
108. Futaki S, Suzuki T, Ohashi W, et al. Arginine-rich peptides. Anabundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem 2001; 276: 5836-40.
109. Mitchell DJ, Kim DT, Steinman L, Fathman CG, Rothbard JB.Polyarginine enters cells more efficiently than other polycationic homopolymers. J Pept Res 2000; 56: 318-25.
110. Crombez L, Aldrian-Herrada G, Konate K, et al. A new potentsecondary amphipathic cell-penetrating peptide for siRNA delivery into mammalian cells. Mol Ther 2009; 17: 95-103.
111. Ziegler A. Thermodynamic studies and binding mechanisms ofcell-penetrating peptides with lipids and glycosaminoglycans. Adv Drug Deliv Rev 2008; 60: 580-97.
112. Hassane FS, Saleh AF, Abes R, Gait MJ, Lebleu B. Cellpenetrating peptides: overview and applications to the delivery of oligonucleotides. Cell Mol Life Sci 2010; 67: 715-26.
113. Holm T, Andaloussi SE, Langel U. Comparison of CPP uptakemethods. Methods Mol Biol 2011; 683: 207-17.
114. Sawant R, Torchilin V. Intracellular transduction using cell-penetrating peptides. Mol Biosyst 2010; 6: 628-40.
115. Console S, Marty C, Garcia-Echeverria C, Schwendener R,Ballmer-Hofer K. Antennapedia and HIV transactivator of transcription (TAT) protein transduction domains promote endocytosis of high molecular weight cargo upon binding to cell surface glycosaminoglycans. J Biol Chem 2003; 278: 35109-14.
116. Ferrari A, Pellegrini V, Arcangeli C, Fittipaldi A, Giacca M, Beltram F. Caveolae-mediated internalization of extracellular HIV-1 tat fusion proteins visualized in real time. Mol Ther 2003; 8: 284-94.
117. Fittipaldi A, Ferrari A, Zoppe M, et al. Cell membrane lipid raftsmediate caveolar endocytosis of HIV-1 Tat fusion proteins. J Biol Chem 2003; 278: 34141-9.
118. Wadia JS, Stan RV, Dowdy SF. Transducible TAT-HA fusogenicpeptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nature medicine 2004; 10: 310-5.
119. Lundin P, Johansson H, Guterstam P, et al. Distinct uptake routesof cell-penetrating peptide conjugates. Bioconjug Chem 2008; 19: 2535-42.
120. Fonseca SB, Pereira MP, Kelley SO. Recent advances in the use ofcell-penetrating peptides for medical and biological applications. Adv Drug Deliv Rev 2009; 61: 953-64.
121. Heitz F, Morris MC, Divita G. Twenty years of cell-penetratingpeptides: from molecular mechanisms to therapeutics. Br J Pharmacol 2009; 157: 195-206.
122. Deshayes S, Konate K, Aldrian G, Crombez L, Heitz F, Divita G. Structural polymorphism of non-covalent peptide-based delivery systems: highway to cellular uptake. Biochim Biophys Acta 2010; 1798: 2304-14.
123. Jarver P, Mager I, Langel U. In vivo biodistribution and efficacy ofpeptide mediated delivery. Trends Pharmacol Sci 2010; 31: 528-35.
124. Wender PA, Galliher WC, Goun EA, Jones LR, Pillow TH. Thedesign of guanidinium-rich transporters and their internalization mechanisms. Adv Drug Deliv Rev 2008; 60: 452-72.
125. Lindahl U. 'Heparin'--from anticoagulant drug into the newbiology. Glycoconj J 2000; 17: 597-605.
126. Park PW, Reizes O, Bernfield M. Cell surface heparan sulfateproteoglycans: selective regulators of ligand-receptor encounters. J Biol Chem 2000; 275: 29923-6.
127. Maget-Dana R. The monolayer technique: a potent tool forstudying the interfacial properties of antimicrobial and membrane-lytic peptides and their interactions with lipid membranes. Biochim Biophys Acta 1999; 1462: 109-40.
128. Van Mau N, Vie V, Chaloin L, Lesniewska E, Heitz F, LeGrimellec C. Lipid-induced organization of a primary amphipathic peptide: a coupled AFM-monolayer study. J Membr Biol 1999; 167: 241-9.
129. Vie V, Van Mau N, Chaloin L, Lesniewska E, Le Grimellec C. Detection of peptide-lipid interactions in mixed monolayers, using isotherms, atomic force microscopy, and fourier transform infrared analyses. Biophys J 2000; 78: 846-56.
130. Magzoub M, Kilk K, Eriksson LE, Langel U, Graslund A. Interaction and structure induction of cell-penetrating peptides in the presence of phospholipid vesicles. Biochim Biophys Acta 2001; 1512: 77-89.
131. Deshayes S, Gerbal-Chaloin S, Morris MC, et al. On themechanism of non-endosomial peptide-mediated cellular delivery of nucleic acids. Biochim Biophys Acta 2004; 1667: 141-7.
132. Ghibaudi E, Boscolo B, Inserra G, et al. The interaction of the cell-penetrating peptide penetratin with heparin, heparansulfates and phospholipid vesicles investigated by ESR spectroscopy. J Pept Sci 2005; 11: 401-9.
133. Terrone D, Sang SL, Roudaia L, Silvius JR. Penetratin and relatedcell-penetrating cationic peptides can translocate across lipid bilayers in the presence of a transbilayer potential. Biochemistry 2003; 42: 13787-99.
134. Thoren PE, Persson D, Isakson P, Goksor M, Onfelt A, Norden B. Uptake of analogs of penetratin, Tat(48-60) and oligoarginine in live cells. Biochem Biophys Res Commun 2003; 307: 100-7.
135. Rothbard JB, Jessop TC, Lewis RS, Murray BA, Wender PA. Roleof membrane potential and hydrogen bonding in the mechanism of translocation of guanidinium-rich peptides into cells. J Am Chem Soc 2004; 126: 9506-7.
136. Deshayes S, Morris MC, Divita G, Heitz F. Cell-penetratingpeptides: tools for intracellular delivery of therapeutics. Cell Mol Life Sci 2005; 62: 1839-49.
137. Barany-Wallje E, Gaur J, Lundberg P, Langel U, Graslund A. Differential membrane perturbation caused by the cell penetrating peptide Tp10 depending on attached cargo. FEBS Lett 2007; 581: 2389-93.
138. Simeoni F, Morris MC, Heitz F, Divita G. Insight into themechanism of the peptide-based gene delivery system MPG: implications for delivery of siRNA into mammalian cells. Nucleic Acids Res 2003; 31: 2717-24.
139. Kwon SJ, Han K, Jung S, et al. Transduction of the MPG-taggedfusion protein into mammalian cells and oocytes depends on amiloride-sensitive endocytic pathway. BMC Biotechnol 2009; 9: 73.
140. Ter-Avetisyan G, Tunnemann G, Nowak D, et al. Cell entry ofarginine-rich peptides is independent of endocytosis. J Biol Chem 2009; 284: 3370-8.
141. Duchardt F, Fotin-Mleczek M, Schwarz H, Fischer R, Brock R. Acomprehensive model for the cellular uptake of cationic cell-penetrating peptides. Traffic 2007; 8: 848-66.
142. Futaki S, Nakase I, Tadokoro A, Takeuchi T, Jones AT. Arginine-rich peptides and their internalization mechanisms. Biochem Soc Trans 2007; 35: 784-7.
143. Amantana A, Moulton HM, Cate ML, et al. Pharmacokinetics,biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer conjugate. Bioconjug Chem 2007; 18: 1325-31.
144. Lebleu B, Moulton HM, Abes R, et al. Cell penetrating peptideconjugates of steric block oligonucleotides. Adv Drug Deliv Rev 2008; 60: 517-29.
145. Jearawiriyapaisarn N, Moulton HM, Buckley B, et al. Sustaineddystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. Mol Ther 2008; 16: 1624-9.
146. Maier MA, Esau CC, Siwkowski AM, et al. Evaluation of basicamphipathic peptides for cellular delivery of antisense peptide nucleic acids. J Med Chem 2006; 49: 2534-42.
147. El Andaloussi S, Lehto T, Mäger I, et al. Design of a peptide-basedvector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo. Nucleic Acids Res 2011; 39: 3972-87.
148. Hayaishi S, Chung H, Kudo M, et al. Oral branched-chain aminoacid granules reduce the incidence of hepatocellular carcinoma and improve event-free survival in patients with liver cirrhosis. Dig Dis 2011; 29: 326-32.
149. Yin H, Saleh AF, Betts C, et al. Pip5 transduction peptides directhigh efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice. Mol Ther 2011; 19: 1295-303.
150. Du L, Kayali R, Bertoni C, et al. Arginine-rich cell-penetratingpeptide dramatically enhances AMO-mediated ATM aberrant splicing correction and enables delivery to brain and cerebellum. Hum Mol Genet 2011; 20: 3151-60.
151. Crisp A, Yin H, Goyenvalle A, et al. Diaphragm rescue aloneprevents heart dysfunction in dystrophic mice. Hum Mol Genet 2011; 20: 413-21.
152. Henke E, Perk J, Vider J, et al. Peptide-conjugated antisenseoligonucleotides for targeted inhibition of a transcriptional regulator in vivo. Nat Biotechnol 2008; 26: 91-100.
153. Crombez L, Morris MC, Dufort S, et al. Targeting cyclin B1through peptide-based delivery of siRNA prevents tumour growth. Nucleic Acids Res 2009; 37: 4559-69.
154. Michiue H, Eguchi A, Scadeng M, Dowdy SF. Induction of in vivosynthetic lethal RNAi responses to treat glioblastoma. Cancer Biol Ther 2009; 8: 2306-13.
155. Moulton HM, Fletcher S, Neuman BW, et al. Cell-penetratingpeptide-morpholino conjugates alter pre-mRNA splicing of DMD (Duchenne muscular dystrophy) and inhibit murine coronavirus replication in vivo. Biochem Soc Trans 2007; 35: 826-8.
156. Burrer R, Neuman BW, Ting JP, et al. Antiviral effects of antisensemorpholino oligomers in murine coronavirus infection models. J Virol 2007; 81: 5637-48.
157. Deas TS, Bennett CJ, Jones SA, et al. In vitro resistance selectionand in vivo efficacy of morpholino oligomers against West Nile virus. Antimicrob Agents Chemother 2007; 51: 2470-82.
158. Kumar P, Wu H, McBride JL, et al. Transvascular delivery ofsmall interfering RNA to the central nervous system. Nature 2007; 448: 39-43.
159. Sazani P, Kang SH, Maier MA, et al. Nuclear antisense effects ofneutral, anionic and cationic oligonucleotide analogs. Nucleic Acids Res 2001; 29: 3965-74.
160. Astriab-Fisher A, Sergueev D, Fisher M, Shaw BR, Juliano RL. Conjugates of antisense oligonucleotides with the Tat and antennapedia cell-penetrating peptides: effects on cellular uptake, binding to target sequences, and biologic actions. Pharm Res 2002; 19: 744-54.
161. Moulton HM, Hase MC, Smith KM, Iversen PL. HIV Tat peptideenhances cellular delivery of antisense morpholino oligomers. Antisense Nucleic Acid Drug Dev 2003; 13: 31-43.
162. Thierry AR, Abes S, Resina S, et al. Comparison of basic peptides-and lipid-based strategies for the delivery of splice correcting oligonucleotides. Biochim Biophys Acta 2006; 1758: 364-74.
163. El-Andaloussi S, Johansson HJ, Lundberg P, Langel U. Inductionof splice correction by cell-penetrating peptide nucleic acids. J Gene Med 2006; 8: 1262-73.
164. Rothbard JB, Kreider E, VanDeusen CL, Wright L, Wylie BL. Arginine-rich molecular transporters for drug delivery: role of backbone spacing in cellular uptake. J Med Chem 2002; 45: 3612-8.
165. Abes S, Moulton HM, Clair P, et al. Vectorization of morpholinooligomers by the (R-Ahx-R)4 peptide allows efficient splicing correction in the absence of endosomolytic agents. J Control Release 2006; 116: 304-13.
166. Wolf Y, Pritz S, Abes S, Bienert M, Lebleu B, Oehlke J. Structuralrequirements for cellular uptake and antisense activity of peptide nucleic acids conjugated with various peptides. Biochemistry 2006; 45: 14944-54.
167. Wu RP, Youngblood DS, Hassinger JN, et al. Cell-penetratingpeptides as transporters for morpholino oligomers: effects of amino acid composition on intracellular delivery and cytotoxicity. Nucleic Acids Res 2007; 35: 5182-91.
168. Abes R, Moulton HM, Clair P, et al. Delivery of steric blockmorpholino oligomers by (R-X-R)4 peptides: structure-activity studies. Nucleic Acids Res 2008; 36: 6343-54.
169. Hassane FS, Ivanova GD, Bolewska-Pedyczak E, et al. A peptide-based dendrimer that enhances the splice-redirecting activity of PNA conjugates in cells. Bioconjug Chem 2009; 20: 1523-30.
170. Saleh AF, Arzumanov A, Abes R, et al. Synthesis and splice-redirecting activity of branched, arginine-rich peptide dendrimer conjugates of peptide nucleic acid oligonucleotides. Bioconjug Chem 2010; 21: 1902-11.
171. Wu B, Lu P, Benrashid E, et al. Dose-dependent restoration ofdystrophin expression in cardiac muscle of dystrophic mice by systemically delivered morpholino. Gene Ther 2010; 17: 132-40.
172. Webster C, Silberstein L, Hays AP, Blau HM. Fast muscle fibersare preferentially affected in Duchenne muscular dystrophy. Cell 1988; 52: 503-13.
173. Armstrong RB, Laughlin MH. Blood flows within and among ratmuscles as a function of time during high speed treadmill exercise. J Physiol 1983; 344: 189-208.
174. Flagg TP, Enkvetchakul D, Koster JC, Nichols CG. Muscle KATPchannels: recent insights to energy sensing and myoprotection. Physiol Rev 2010; 90: 799-829.
175. Wu B, Moulton HM, Iversen PL, et al. Effective rescue ofdystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer. Proc Natl Acad Sci USA 2008; 105: 14814-9.
176. Samoylova TI, Smith BF. Elucidation of muscle-binding peptidesby phage display screening. Muscle Nerve 1999; 22: 460-06.
177. Yin H, Moulton HM, Betts C, et al. A fusion peptide directsenhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice. Hum Mol Genet 2009; 18: 4405-14.
178. Yin H, Betts C, Saleh AF, et al. Optimization of peptide nucleicacid antisense oligonucleotides for local and systemic dystrophin splice correction in the mdx mouse. Mol Ther 2010; 18: 819-27.
179. Eagle M, Baudouin SV, Chandler C, Giddings DR, Bullock R, Bushby K. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact ofhome nocturnal ventilation. Neuromuscul Disord 2002; 12: 926-9.
180. Malerba A, Boldrin L, Dickson G. Long-Term Systemic Administration of Unconjugated Morpholino Oligomers for Therapeutic Expression of Dystrophin by Exon Skipping in Skeletal Muscle: Implications for Cardiac Muscle Integrity. Nucleic Acid Ther (Formerly Oligonucleotides) 2011; 21: 293-8.
181. Wu B, Xiao B, Cloer C, et al. One-year Treatment of Morpholino Antisense Oligomer Improves Skeletal and Cardiac Muscle Functions in Dystrophic mdx Mice. Mol Ther 2011; 19: 576-83.
182. Jearawiriyapaisarn N, Moulton HM, Sazani P, Kole R, Willis MS. Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers. Cardiovas Res 2010; 85: 444-53.
183. Ivanova GD, Arzumanov A, Abes R, et al. Improved cellpenetrating peptide-PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle. Nucleic Acids Res 2008; 36: 6418-28.
184. Ma W, Lin Y, Xuan W, Iversen PL, Smith LJ, Benchimol S. Inhibition of p53 expression by peptide-conjugated phosphorodiamidate morpholino oligomers sensitizes human cancer cells to chemotherapeutic drugs. Oncogene 2011; In press.
185. Kole R, Krainer AR, Altman S. RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov 2012; 11: 125-40.
186. Moulton HM, Moulton JD. Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy. Biochim Biophys Acta 2010; 1798: 2296-303.
187. Mann CJ, Honeyman K, Cheng AJ, et al. Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc Natl Acad Sci USA 2001; 98: 42-7.
188. Morris MC, Vidal P, Chaloin L, Heitz F, Divita G. A new peptide vector for efficient delivery of oligonucleotides into mammalian cells. Nucleic Acids Res 1997; 25: 2730-6.
189. Mae M, El Andaloussi S, Lundin P, et al. A stearylated CPP for delivery of splice correcting oligonucleotides using a non-covalent co-incubation strategy. J Control Release 2009; 134: 221-7.
190. Lehto T, Abes R, Oskolkov N, et al. Delivery of nucleic acids with a stearylated (RxR)4 peptide using a non-covalent co-incubation strategy. J Control Release 2010; 141: 42-51.
191. El Andaloussi S, Said Hassane F, Boisguerin P, Sillard R, Langel U, Lebleu B. Cell-penetrating peptides-based strategies for the delivery of splice redirecting antisense oligonucleotides. Methods Mol Biol 2011; 764: 75-89.
192. Hassane FS, Abes R, El Andaloussi S, et al. Insights into the cellular trafficking of splice redirecting oligonucleotides complexed with chemically modified cell-penetrating peptides. J Control Release 2011; 153: 163-72.
193. Lehto T, Simonson OE, Mager I, et al. A peptide-based vector for efficient gene transfer in vitro and in vivo. Mol Ther 2011; 19: 1457-67.
194. Ezzat K, Andaloussi SE, Zaghloul EM, et al. PepFect 14, a novel cell-penetrating peptide for oligonucleotide delivery in solution and as solid formulation. Nucleic Acids Res 2011; 39: 5284-98.
195. Soomets U, Lindgren M, Gallet X, et al. Deletion analogues of transportan. Biochim Biophys Acta 2000; 1467: 165-76.
196. Abes S, Turner JJ, Ivanova GD, et al. Efficient splicing correction by PNA conjugation to an R6-Penetratin delivery peptide. Nucleic Acids Res 2007; 35: 4495-502.
197. Fletcher S, Honeyman K, Fall AM, et al. Morpholino oligomermediated exon skipping averts the onset of dystrophic pathology in the mdx mouse. Mol Ther 2007; 15: 1587-92.
198. Yin H, Moulton HM, Seow Y, et al. Cell-penetrating peptideconjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. Hum Mol Genet 2008; 17: 3909-18.
199. Yin H, Moulton HM, Betts C, et al. Functional rescue of dystrophin-deficient mdx mice by a chimeric peptide-PMO. Mol Ther 2010; 18: 1822-9